Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie av utredningsmedel hos deltagare med tidigare behandlad icke-småcellig lungcancer i stadium IV (NSCLC) (MK-3475-01H/KEYMAKER-U01)

5 november 2026 uppdaterad av: Merck Sharp & Dohme LLC

KEYMAKER-U01 Delstudie 01H: En fas 2, randomiserad, paraplystudie med rullande armar av undersökningsagenter hos deltagare med tidigare behandlade stadium IV icke-småcellig lungcancer (NSCLC)

Researchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs.

Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing.

However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells.

Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn:

  • About the safety of the study treatments and if people tolerate them
  • How many people have the cancer respond to the study treatments

Studieöversikt

Detaljerad beskrivning

The master screening protocol is MK-3475-U01 (KEYMAKER-U01) - NCT04165798

Studietyp

Interventionell

Inskrivning (Beräknad)

96

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Region M. de Santiago
      • Santiago, Region M. de Santiago, Chile, 7500653
        • Centro de Estudios Clínicos SAGA ( Site 0161)
      • Santiago, Region M. de Santiago, Chile, 7500921
        • Fundación Arturo López Pérez ( Site 0160)
      • Santiago, Region M. de Santiago, Chile, 8420383
        • Bradfordhill ( Site 0162)
    • Kentucky
      • Lexington, Kentucky, Förenta staterna, 40536-0293
        • University of Kentucky Chandler Medical Center ( Site 0019)
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21237
        • MedStar Franklin Square Medical Center ( Site 0033)
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Förenta staterna, 15212
        • AHN Cancer Institute - Allegheny General ( Site 9501)
    • Texas
      • Dallas, Texas, Förenta staterna, 75246-2046
        • Texas Oncology - DFW ( Site 8003)
      • Thessaloniki, Grekland, 570 01
        • European Interbalkan Medical Center ( Site 0205)
    • Attica
      • Athens, Attica, Grekland, 115 27
        • THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 0204)
      • Haifa, Israel, 3109601
        • Rambam Health Care Campus ( Site 0076)
      • Jerusalem, Israel, 9103102
        • Shaare Zedek Medical Center ( Site 0075)
      • Kfar Saba, Israel, 4428164
        • Meir Medical Center ( Site 0071)
      • Petah Tikva, Israel, 4941492
        • Rabin Medical Center ( Site 0074)
      • Ramat Gan, Israel, 5265601
        • Sheba Medical Center ( Site 0070)
      • Tel Aviv, Israel, 6423906
        • Sourasky Medical Center ( Site 0077)
      • Florence, Italien, 50134
        • Azienda Ospedaliera Universitaria Careggi ( Site 0173)
      • Milan, Italien, 20132
        • Ospedale San Raffaele. ( Site 0171)
      • Roma, Italien, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0174)
    • Lombardy
      • Milan, Lombardy, Italien, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0175)
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polen, 60-569
        • Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 0153)
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polen, 02-781
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)
    • Pomeranian Voivodeship
      • Gdansk, Pomeranian Voivodeship, Polen, 80-214
        • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
    • West Pomeranian Voivodeship
      • Koszalin, West Pomeranian Voivodeship, Polen, 75-581
        • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 0152)
      • Madrid, Spanien, 28223
        • Hospital Universitario Quiron Madrid ( Site 0091)
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Spanien, 08908
        • Institut Català d'Oncologia - L'Hospitalet ( Site 0090)
      • Adana, Turkiet (Türkiye), 01250
        • Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 0141)
      • Ankara, Turkiet (Türkiye), 06230
        • Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 0140)
      • Ankara, Turkiet (Türkiye), 06800
        • Ankara Bilkent Şehir Hastanesi. ( Site 0142)
      • Istanbul, Turkiet (Türkiye), 34098
        • I. U. Cerrahpasa Tip Fakultesi ( Site 0144)
      • Izmir, Turkiet (Türkiye), 35100
        • Ege Universitesi Hastanesi ( Site 0143)
      • Berlin, Tyskland, 13353
        • Charite-Universitaetsmedizin Berlin ( Site 0191)
    • Baden-Wurttemberg
      • Tübingen, Baden-Wurttemberg, Tyskland, 72076
        • Universitaetsklinik Tuebingen ( Site 0192)
    • Bács-Kiskun county
      • Kecskemét, Bács-Kiskun county, Ungern, 6000
        • Bacs-Kiskun Varmegyei Oktatokorhaz ( Site 0063)
    • Győr-Moson-Sopron
      • Győr, Győr-Moson-Sopron, Ungern, 9024
        • Petz Aladar Egyetemi Oktato Korhaz ( Site 0062)
    • Jász-Nagykun-Szolnok
      • Szolnok, Jász-Nagykun-Szolnok, Ungern, 5000
        • Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet ( Site 0061)
    • Pest County
      • Törökbálint, Pest County, Ungern, 2045
        • Református Pulmonológiai Centrum ( Site 0064)

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Histologically or cytologically confirmed diagnosis of Stage IV nonsquamous non-small cell lung cancer (NSCLC)
  • Documented disease progression per RECIST 1.1 after receiving an anti-programmed cell death 1 protein (PD-1)/programmed cell death ligand 1 (PD-L1) treatment and platinum-based chemotherapy
  • Confirmation per local test report that epidermal growth factor receptor negative (EGFR-), anaplastic lymphoma kinase negative (ALK-), c ros oncogene 1 negative (ROS1-), or other directed therapy is not indicated as primary therapy
  • Measurable disease per RECIST 1.1 as assessed by investigator and verified by BICR
  • Life expectancy of at least 3 months
  • An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization
  • Is an individual of any sex/gender who is at least 18 years of age at the time of providing the informed consent
  • Has adequate organ function
  • If capable of producing sperm refrains from donating sperm plus either abstains from penile-vaginal intercourse or uses a penile/external condom, with contraceptive use consistent with local regulations
  • Participant/participants of childbearing potential (POCBP) is not pregnant and has a negative highly sensitive pregnancy test; and is not breastfeeding and uses a highly effective contraceptive method
  • Archival tumor tissue sample of a tumor lesion not previously irradiated has been provided
  • Has provided tissue prior to treatment randomization from a newly obtained formalin-fixed sample from a new biopsy
  • Human Immunodeficiency Virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
  • Participants who are hepatitis B surface antigen (HBsAg) positive have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
  • Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
  • Received radiation therapy to the lung
  • Has uncontrolled or significant cardiovascular disorder prior to randomization
  • Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  • Participants who have adverse events (AEs) (other than alopecia) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline
  • Has known severe hypersensitivity (≥Grade 3) to study intervention and/or any of its excipients
  • Has clinically significant corneal disease
  • Has received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids
  • Has inadequate washout period prior to randomization
  • Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
  • Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
  • Has previously received docetaxel as monotherapy or in combination with other therapies
  • Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
  • Has known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has evidence of any leptomeningeal disease
  • Has history of interstitial lung disease (ILD)/pneumonitis, current diagnosis of ILD, and/or suspected ILD
  • Has active autoimmune disease that has required systemic treatment in the past 2 years
  • Has active infection requiring systemic therapy
  • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease
  • Has known history of, or active, neurologic paraneoplastic syndrome
  • Has history of allogeneic tissue/solid organ transplant
  • Have not adequately recovered from major surgery or have ongoing surgical complications

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Raludotatug Deruxtecan

Participants receive raludotatug deruxtecan (R-DXd) 5.6 mg/kg via intravenous (IV) Infusion every 3 weeks (q3w) until disease progression or discontinuation criterion is met.

IV Infusion

Andra namn:
  • R-DXd
  • DS-6000a
  • MK-5909

Administered as a rescue medication per approved product label before R-DXd or I-DXd infusion

Andra namn:
  • 5-HT3-receptorantagonist

Administered as a rescue medication per approved product label before R-DXd or I-DXd infusion

Andra namn:
  • NK-1-receptorantagonist

Administered as a rescue medication per approved product label before R-DXd or I-DXd infusion, and for 3 days starting 1 day prior to docetaxel administration

Experimentell: Ifinatamab Deruxtecan

Participants receive ifinatamab deruxtecan (I-DXd) 12 mg/kg via IV infusion q3w until disease progression or discontinuation criterion is met.

Administered as a rescue medication per approved product label before R-DXd or I-DXd infusion

Andra namn:
  • 5-HT3-receptorantagonist

Administered as a rescue medication per approved product label before R-DXd or I-DXd infusion

Andra namn:
  • NK-1-receptorantagonist

Administered as a rescue medication per approved product label before R-DXd or I-DXd infusion, and for 3 days starting 1 day prior to docetaxel administration

IV Infusion

Andra namn:
  • DS-7300a
  • I-DXd
  • MK-2400
Aktiv komparator: Docetetaxel

Participants receive docetaxel 75mg/m2 via IV infusion q3w until disease progression or discontinuation criterion is met.

Administered as a rescue medication per approved product label before R-DXd or I-DXd infusion, and for 3 days starting 1 day prior to docetaxel administration

IV Infusion

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Objective Response Rate (ORR)
Tidsram: Up to approximately 81 months

ORR is defined as the percentage of participants with Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

Up to approximately 81 months
Percentage of Participants with at Least One Adverse Event (AE)
Tidsram: Up to approximately 81 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The percentage of participants who experience an AE will be reported.

Up to approximately 81 months
Percentage of Participants Who Discontinued Medication Due to an AE
Tidsram: Up to approximately 24 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The percentage of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 24 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Duration of Response (DOR)
Tidsram: Up to approximately 81 months

For participants who demonstrate a confirmed CR (disappearance of all target lesions) or (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

Up to approximately 81 months
Progression-free Survival (PFS)
Tidsram: Up to approximately 81 months

PFS is defined as the time from randomization to the first documented PD or death due to any cause, whichever occurs first as assessed by RECIST 1.1. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

Up to approximately 81 months
Overall Survival (OS)
Tidsram: Up to approximately 81 months

OS is defined as the time from randomization to death due to any cause.

Up to approximately 81 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Studierektor: Medical Director, Merck Sharp & Dohme LLC

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

13 maj 2025

Primärt slutförande (Beräknad)

12 mars 2032

Avslutad studie (Beräknad)

12 mars 2032

Studieregistreringsdatum

Först inskickad

13 januari 2025

Först inskickad som uppfyllde QC-kriterierna

13 januari 2025

Första postat (Faktisk)

17 januari 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera